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Abstract
Integrating single nucleotide polymorphism (SNP) p-values from genome-wide association
studies (GWAS) across genes and pathways is a strategy to improve statistical power and
gain biological insight. Here, we present Pascal (Pathway scoring algorithm), a powerful
tool for computing gene and pathway scores from SNP-phenotype association summary
statistics. For gene score computation, we implemented analytic and efficient numerical
solutions to calculate test statistics. We examined in particular the sum and the maximum of
chi-squared statistics, which measure the strongest and the average association signals
per gene, respectively. For pathway scoring, we use a modified Fisher method, which offers
not only significant power improvement over more traditional enrichment strategies, but
also eliminates the problem of arbitrary threshold selection inherent in any binary member-
ship based pathway enrichment approach. We demonstrate the marked increase in power
by analyzing summary statistics from dozens of large meta-studies for various traits. Our
extensive testing indicates that our method not only excels in rigorous type I error control,
but also results in more biologically meaningful discoveries.
Author Summary
Genome-wide association studies (GWAS) typically generate lists of trait- or disease-asso-
ciated SNPs. Yet, such output sheds little light on the underlying molecular mechanisms
and tools are needed to extract biological insight from the results at the SNP level. Pathway
analysis tools integrate signals from multiple SNPs at various positions in the genome in
order to map associated genomic regions to well-established pathways, i.e., sets of genes
known to act in concert. The nature of GWAS association results requires specifically tai-
lored methods for this task. Here, we present Pascal (Pathway scoring algorithm), a tool
that allows gene and pathway-level analysis of GWAS association results without the need
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to access the original genotypic data. Pascal was designed to be fast, accurate and to have
high power to detect relevant pathways. We extensively tested our approach on a large col-
lection of real GWAS association results and saw better discovery of confirmed pathways
than with other popular methods. We believe that these results together with the ease-of-
use of our publicly available software will allow Pascal to become a useful addition to the
toolbox of the GWAS community.
Introduction
Genome-wide association studies (GWAS) have linked a large number of common genetic var-
iants to various phenotypes. For most common phenotypes, high-powered meta-analyses have
revealed tens to hundreds of single nucleotide polymorphisms (SNPs) with robust associations.
However, deriving biological knowledge from these associations is often challenging[1,2].
Many genes function in multiple biological processes and it is typically not clear which of these
processes is related to the phenotype in question.
Pathway analysis aims to provide insight into the biological processes involved by aggregat-
ing the association signal observed for a collection of SNPs into a pathway level signal. This is
generally carried out in two steps: first, individual SNPs are mapped to genes and their associa-
tion p-values are combined into gene scores; second, genes are grouped into pathways and
their gene scores are combined into pathway scores. Existing tools vary in the methods
used for each step and the strategies employed to correct for correlation due to linkage
disequilibrium.
SNPs are usually mapped to genes based on physical distance[3], linkage disequilibrium
(LD)[4], or a combination of both[5]. Genes are commonly assigned to pathways using well-
established databases (such as Gene Ontology[6], KEGG[7], PANTHER[8], REACTOME[9],
BIOCARTA[10]) or in-house annotation (based on co-expression[4], for example).
Various methods have been developed to aggregate SNP summary statistics into gene scores
[3,11,12]. A common aggregation method is to use only the most significant SNP within a win-
dow encompassing the gene of interest, for example by assigning the maximum-of-chi-squares
(MOCS) as the gene score statistic[3,13] (the contributing chi-squared values can be obtained
from SNP p-values by using the inverse chi-squared quantile transformation). Another method
is to combine results for all SNPs in the gene region, for example by using the sum-of-chi-
squares (SOCS) statistic[14]. Both the MOCS and SOCS statistics are confounded by several
properties of the gene. Specifically, in both cases it is important to correct for gene size and LD
structure to obtain a well-calibrated p-value for the statistic. In the remainder of this paper, we
also refer to the p-values of the MOCS and the SOCS statistics asmax and sum gene scores,
respectively. P-values can be estimated by phenotype label permutation, but this method is
both computationally intensive and requires access to genotype data of the actual study, which
are rarely shared[15]. Thus, one often has access only to association summary statistics and not
the individual genotypes. In this case, one method is to regress out confounding factors[3].
This approach is employed in the popular MAGENTA tool, but provides only a partial solution
as substantial residual confounding still remains[3].
An alternative approach, which we take here, is to exploit the fact that the null distributions
of the MOCS and SOCS statistics depend solely on the pairwise correlation matrix of the con-
tributing genotypes. In the absence of the original genotypes, this correlation matrix can still be
estimated from ethnicity-matched, publicly available genotypic data, as has been proposed by
us and others for conditional multi-SNP analysis of GWAS results[16,17]. This approach has
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been implemented in the Versatile Gene-based Association Study (VEGAS) software and yields
results close to those from phenotype label permutation[11]. However, while VEGAS is faster
than estimation via phenotype label permutation, it still relies on a Monte Carlo method for
estimating the p-values. This limits its efficiency for highly significant gene scores.
Once gene scores have been computed, pathway analysis tools use various strategies to
aggregate them across sets of related genes. The most common approach used for analysing
GWAS meta-analysis results, as exemplified by the popular GWAS pathway analysis tool
MAGENTA, is based on binary enrichment tests, which rely on a threshold parameter to
define which genes are significantly associated with the trait[3,18]. However, with this strategy
potential contributions of weakly associated genes that just missed the threshold are lost and
there is no clear guidance on how the threshold parameter should be set. Indeed, it seems com-
mon practice to keep the default parameter without knowing whether other choices would pro-
duce better results[5].
In this work, we focus on improving two major aspects of pathway enrichment analysis (Fig
1). First, we incorporate numerical and analytic solutions for the p-value estimation of the
MOCS and SOCS statistics. This removes the need for phenotype permutations or Monte
Carlo simulations, thereby making the score computation faster. Second, we developed a rigor-
ous type I error control strategy and implemented a modified Fisher method to compute
parameter-free pathway scores[19]. While some elements of our algorithm have been proposed
Fig 1. Overview of the methodology to compute gene and pathway scores. a) We compute gene scores by aggregating SNP p-values from a GWAS
meta-analysis (without the need for individual genotypes), while correcting for linkage disequilibrium (LD) structure. To this end, we use numerical and
analytic solutions to compute gene p-values efficiently and accurately given LD information from a reference population (e.g. one provided by the 1000
Genomes Project[22]). Two options are available: the max and sum of chi-squared statistics, which are based on the most significant SNP and the average
association signal across the region, respectively. b) We use external databases to define gene sets for each reported pathway. We then compute pathway
scores by combining the scores of genes that belong to the same pathways, i.e. gene sets. The fast gene scoring method allows us to dynamically
recalculate gene scores by aggregating SNP p-values across pathway genes that are in LD and thus cannot be treated independently. This amounts to
fusing the genes and computing a new score that takes the full LD structure of the corresponding locus into account. We evaluate pathway enrichment of
high-scoring (possibly fused) genes using one of two parameter-free procedures (chi-squared or empirical score), avoiding any p-value thresholds inherent
to standard binary enrichment tests.
doi:10.1371/journal.pcbi.1004714.g001
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in other fields of statistical genetics[20,21], the novelty of our method lies in the unique combi-
nation of sophisticated analytical methods employed for pathway analysis, which results in
improved computational speed, precision, type I error control and power.
In the following, we first evaluate the performance of our tool, demonstrating its speed
gains and robust control of type I error. Then, using precision-recall analyses, comparing small
to large GWAS results for lipid traits and Crohn’s disease, we demonstrate that our pathway
scoring approach exhibits a gain in power compared to binary enrichment. Finally, we apply
our method to dozens of large meta-analysis studies and evaluate power by counting the num-
ber of pathways passing the Bonferroni-corrected p-value threshold.
We provide this tool for gene and pathway scoring as a standalone, open-source software
package called Pascal.
Results
Pascal computes genes scores rapidly and to very high precision
First, we compared the run time and precision of Pascal to those of VEGAS[11], one of the cur-
rent state-of-the-art gene scoring tools. To this end, we applied both procedures to genome-
wide p-values obtained from two large-scale GWAS meta-analyses: The first used about 2.5
million HapMap imputed SNPs[23,24] and the second was based on about 6.4 million SNPs
imputed based on a common subset of 1000 Genomes Project (1KG) panel[22,25]. As bench-
mark we used the results from VEGAS for the former and VEGAS2 (a recent implementation
of VEGAS that uses pre-computed LD matrices from 1KG[26]) for the latter. We observed a
substantially smaller run time for our method in both cases (Fig 2A): for the HapMap imputed
data, VEGAS took 29 hours to compute 18,132 gene scores, while Pascal was considerably
faster, needing only about 30 minutes for either statistical test (sum or max) on a single core
(Intel Xeon CPU, 2.8GHz). For the 1KG imputed data, Pascal finished the computation in
under two hours for either statistic, whereas VEGAS2 took over ten days.
To compare the gene scores computed by the two methods, we increased the maximum
number of Monte Carlo runs for VEGAS to 108, at a high computational cost (about 9 days of
runtime). We observed excellent concordance between the gene scores of Pascal and VEGAS,
Fig 2. Comparing efficiency between VEGAS and Pascal. a) Run times of VEGAS and Pascal (both
options). Gene scores were computed on two GWAS (one HapMap imputed[23], one 1KG imputed[22,25])
for 18,132 genes on a single core. Pascalwas compared to VEGAS for the HapMap imputed study and
VEGAS2 for the 1KG-imputed study. For this plot, VEGAS and VEGAS2 were used with the default
maximum number of Monte Carlo samples of 106 for both studies and additionally with 108 Monte Carlo
samples for the HapMap imputed study. b) Scatter plot of -log10-transformed gene p-values for the sum gene
scores obtained by VEGAS and Pascal, respectively. P-values above 10−6 are in excellent concordance.
Below this value VEGAS could not give precise estimates, since it was run with the maximal number of Monte
Carlo samples set to 108.
doi:10.1371/journal.pcbi.1004714.g002
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except for scores below 10−6: since we restricted VEGAS to 108 Monte Carlo runs, it could not
estimate p-values smaller than 10−6 with good precision (Fig 2B). In contrast, Pascal can com-
pute gene scores with high precision for p-values down to 10−15. In summary, the analytic solu-
tions incorporated in the Pascal algorithm offer a dramatic increase in efficiency and precision.
Direct comparison of the sum and max gene scores of Pascal revealed good concordance
between the two scoring methods. In cases where the results of two methods disagree, max
scores tend to be more significant (S3 Fig).
The results reported here are all based on GWAS of European cohorts, thus we used the
European panel from 1KG as reference panel. To evaluate whether this panel approximates LD
matrices derived from other European cohorts sufficiently well, we compared results when
using genotypes taken from the CoLaus cohort as reference panel[27]. We saw good concor-
dance between the different reference panels for both the sum and the max gene scores for the
largest HDL blood lipid GWAS to-date[23] (S2 Fig).
Pascal controls for inflation due to neighbouring genes
In general, methods that compute pathway scores from gene scores assume independence of
these scores under the null hypothesis. However, neighbouring genes often have correlated scores
due to LD, and are sometimes part of the same pathway. This results in a non-uniform pathway
score p-value distribution under the null hypothesis. MAGENTA deals with this problem by
pruning gene scores based on LD and using only the highest gene score in the region. However,
this introduces a bias toward high gene scores into the calculation of pathway scores[3].
Our fast gene score calculation allows us to address this issue with a gene-fusion strategy. In
brief, for each pathway harbouring correlated genes, gene scores are recomputed jointly for
each correlated gene set (i.e. fusion-gene) using the same method as for individual genes (Fig
1B, Methods), thus taking the full LD structure of the corresponding region into account.
To see if our approach provides well-calibrated p-values, we simulated random phenotypes
and calculated association p-values for all 1KG SNPs. We then employed our pathway analysis
pipeline and checked if pathway p-values were uniformly distributed, as expected for random
phenotypes. We found that without the gene-fusion strategy, pathway p-values are indeed
inflated and, as expected, this inflation is stronger for pathways with many proximal genes (Fig
3A). In contrast, applying the gene-fusion strategy corrects the distribution of pathway score
p-values to be uniform irrespective of the number of proximal genes (Fig 3B). Importantly, we
did not see inflation for very small p-values with the gene-fusion strategy, which is essential for
type I error control.
Going one step further, we also simulated in-silico phenotypes influenced by randomly
selected causal SNPs. We explored two scenarios: one where 50 SNPs were randomly selected
from the entire genome and another where random sampling was applied to gene regions only.
The experiment was repeated 50 times and independent genetic data was used to generate the
estimated pairwise correlation. Although in this case gene scores naturally deviate from the
null distribution, we found that overall pathway p-values remain well calibrated (S14 and S15
Figs). Note that we explored only a limited set of simulation scenarios and cannot exclude that
some settings might produce less well-calibrated results (see legend of S15 Fig).
Pascal has higher sensitivity and specificity than hypergeometric
pathway enrichment tests
A commonly used statistic to derive pathway scores from a ranked list of genes (or SNPs) is to
first apply a fixed threshold in order to define a subset of elements that is considered to be sig-
nificantly associated with the given trait. The pathway statistic is then computed using a
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hypergeometric test evaluating whether the pathway contains more significant elements than
expected. This approach is implemented, for example, in the tool MAGENTA[3]. Another
common strategy is to use the rank-sum (Wilcoxon) test[3,28,29].
As described above, Pascal computes aggregate statistics without the need for defining a set
of significant genes. We thus sought to compare this strategy with methods based on the hyper-
geometric or rank-sum tests. To this end, we tested performance on association results for four
blood lipid traits obtained from of the CoLaus cohort[27]. We used a large meta-analysis of
188,577 individuals to define a reference set of associated pathways for each of the four lipid
traits[23]. We then applied both pathway analysis methods to three non-overlapping, small
subsets (1500 individuals) of the CoLaus study and compared how well the resulting pathways
matched the reference set from the large study. We used the area under the precision-recall
curve (AUC-PR) to quantify the performance of each method. Note that our choice was driven
by the fact that precision-recall curves are preferred over receiver-operator-characteristic
(ROC) curves when only a small fraction of tested pathways are in the reference set[30]. Our
results show that Pascal outperforms both the hypergeometric and rank-sum based approaches
(Fig 4A). Importantly, the better performance of Pascal is observed across a range of thresholds
defining significant genes, including the optimal choice which is variable and a priori unknown
across the different lipid phenotypes.
We applied the same evaluation strategy for GWAS data on Crohn’s disease. We used the
currently largest GWAS for Crohn’s disease[31] to define a reference standard of associated
Fig 3. Pathway scores for random phenotypes. As input data we used 100 simulated instances of a
randomGaussian phenotype and genotype data for 379 individuals from the EUR-1KG panel. Using the
Pascal pipeline with sum gene scores and chi-squared pathway integration strategy we computed p-values
for 1,077 pathways from our pathway library (results for max gene scores are similar, see S4 Fig). Panel (a)
shows the p-value distributions without merging of neighbouring genes and (b) with merging of neighbouring
genes (gene-fusion strategy).P-value distributions are represented by QQ-plots (upper panels) and
histograms (lower panels). Results are colour-coded according to the fraction of genes in a given pathway
that have a neighbouring gene in the same pathway, i.e. that are located nearby on the genome (distance
<300kb). (a) P-values of pathways that contain genes in LD are strongly inflated without correction. (b) The
gene fusion approach provides well-calibrated p-values independently of the number of pathway genes in
LD.
doi:10.1371/journal.pcbi.1004714.g003
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pathways. We then applied both pathway analysis methods to results from two individual
cohorts participating in the meta-analysis that contained at least 1000 cases[31–33]. We
observed that the chi-squared-method performed at least as well as all other strategies in this
setting (Fig 4B). Overall, we saw similar results for both max and sum gene scores (S5 Fig).
Pascal has higher power than hypergeometric test based pathway
enrichment in a wide range of traits
Having established that Pascal accurately controls type I error rate for simulated phenotypes
and better recovers truly associated pathways for blood lipid traits as well as Crohn’s disease,
we next sought to evaluate its power when applied to large meta-analytic studies on a broad
range of traits, where no ground truth can be defined.
To this end, we compared Pascal with the methods based on the hypergeometric test (using
9 different threshold values) and the rank-sum test proposed by Segrè et al.[3] for 118 GWAS
Fig 4. Performance of pathway enrichment methods for blood lipid traits and Crohn’s disease.
Displayed is the mean area under the precision-recall curve (AUC) for pathways identified using Pascal, a
standard hypergeometric test at various gene score threshold levels, and a rank-sum test (vertical bars show
the standard error). We show results for the max gene scores (sum gene score results are similar, see S5
Fig). a) Results for four blood lipid traits. The gold standard pathway list was defined as all pathways that
show a significance level below 5×10−6 for any of the tested threshold parameters for hypergeometric tests in
the largest study of lipid traits to date[23]. The significance level of 5×10−6 corresponds to the Bonferroni
corrected, genome-wide significance threshold at the 0.5% level for a single method. For each phenotype,
error bars denote the standard error computed from three independent subsamples of theCoLaus study
(including 1500 individuals each). We see good overall performance of Pascal pathway scores, whereas
results for discrete gene sets vary widely with the particular choice for the threshold parameter of
hypergeometric test. b) Results for Crohn’s disease using the same approach as in (a). A reference standard
pathway list was defined as in (a) using the largest study of Crohn’s disease traits to date[31]. We observe
that the chi-squared strategy performs at least as well as all other strategies in this setting, whereas
performance of the hypergeometric testing strategy varies.
doi:10.1371/journal.pcbi.1004714.g004
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(S1 Table). All GWAS were derived from European populations justifying the use of the Euro-
pean 1KG genotypes as reference population. For a given GWAS, we asked how many tested
pathways reached genome-wide significance at the Bonferroni-corrected p-value threshold of
0.05. Our results indicate that globally our approach has higher power than either the methods
using the hypergeometric test (across all tested thresholds), or the rank-sum test (Figs 5A and
S6). For individual traits (Fig 5B), specific choices of the threshold parameter of the hypergeo-
metric test sometimes reveal more pathways, but again the value of the optimal threshold varies
across traits and cannot be known a priori.
When splitting the GWAS into high powered (more than 50,000 individuals) and low pow-
ered studies (less than 50,000 individuals), we saw that in both cases we gain power by using
Pascal although the effect was more pronounced for low powered GWAS (S7 Fig).
Hypergeometric enrichment testing is hampered by the fact that the optimal threshold is
not known in advance. A strategy to overcome this could be to merge hypergeometric pathway
scores coming from different sets of thresholds, further corrected for the effective size of the
threshold sets. While such an aggregated hypergeometric testing improved performance, it was
still outperformed by Pascal (S10 and S11 Figs).
Fig 5. Power of pathway scoringmethods across diverse traits and diseases. Bar heights represent the number of pathways found to be significant
after Bonferroni-correction. Within a given trait group, results are aggregated for all tested GWAS studies. 65 GWAS had at least one significant pathway in
one of the tested methods. For each GWAS, the raw number of significant pathways was divided by the number of pathways found by the best performing
method. This was done in order to avoid that a few studies with many emerging pathways dominate. We show results for the MOCS gene scores (SOCS
gene score results are similar, see S6 Fig). (a) Results are aggregated over all trait groups. (b) Results for different trait groups.
doi:10.1371/journal.pcbi.1004714.g005
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One of the proposed pathway scoring methods transforms the ranked gene p-values such
that they follow a chi-squared distribution. The chi-squared distribution is a special case of the
Gamma distribution with shape parameter 0.5. Thus we also examined whether using other
shape parameters of the Gamma distribution could improve performance (see Methods, S12
and S13 Figs). This analysis suggested that the chi-squared pathway scoring method represents
a good compromise for a wide range of genetic architectures.
We found numerous examples of biologically plausible pathways discovered by Pascal that
were not found by a standard binary enrichment analysis (Fig 6, S2 Table). For insulin resis-
tance[34] we found the REACTOME pathway insulin signal attenuation to be genome-wide
significant. Notably, none of the genes in this pathway was found to contain a genome-wide
significant SNP in the original publication. Another example is bone mineral density in
women (LS-BMD)[35]. We found the Hedgehog andWnt pathways to be significant, both of
which are known to be involved in osteoblast biology[36]. Again, standard binary enrichment
did not reach genome-wide significance. For smoking behaviour (measured in cigarettes per
day)[37], we found pathways related to nicotinic acetylcholine receptors. For macular degenera-
tion, we found lipoprotein and complement system involvement, which both have support in
the literature[38,39]. These examples illustrate that the improvements made by Pascal not only
lead to better performance on benchmarks, but may also have a dramatic impact on the inter-
pretation of GWAS results in practice.
Fig 6. Examples of pathway enrichments comparing Pascal (chi-squared method) to the hypergeometric method.Displayed are results for four
phenotypes showing improvement when using Pascal instead of the hypergeometric (binary) enrichment strategy at the 5% threshold level. Underlying gene
scores were calculated using the summethod. Dashed lines refer to the Bonferroni significance level when correcting for the number of pathways (1077).
Besides from few cancer-related pathways, all pathways highlighted by this analysis have been implied by prior research (see main text). (a) For the trait
insulin resistance, Pascal scored the pathway insulin signal attenuation first, followed by two other trait-relevant pathways (PI3K AKT activation and insulin
receptor signaling), while the hypergeometric test did not find any significant pathways. (b) For smoking amount (number of cigarettes per day), Pascal
revealed three significant pathways related to nicotinic acetylcholine receptors. (c) For osteoporosis, two cancer-related pathways scored significant using
both Pascal and the hypergeometric test, but only Pascal revealed theWNT and Hedgehog signaling pathways, which are known to be involved in osteoblast
biology. (d) Formacular degeneration, Pascal found three significant, trait-relevant pathways related to lipoproteins and the complement system.
doi:10.1371/journal.pcbi.1004714.g006
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Discussion
In this work, we presented a new tool called Pascal (Pathway scoring algorithm) that specifi-
cally addresses both gene scoring and pathway enrichment, making significant advancement
with respect to the state-of-the-art:
First, our gene score calculation combines analytical and numerical solutions to properly
correct for multiple testing on correlated data[21]. While some of these approaches have
already been applied within the rare variant field[20] (typically in a gene-wise fashion) we pro-
vide a streamlined implementation that can run genome-wide analyses without the need for
any Monte Carlo simulations (making it about 100 times faster and more precise than the
widely used software VEGAS).
Second, our pathway scoring integrates individual gene scores without the need for a tune-
able threshold parameter to dichotomize gene scores for binary membership enrichment
analysis (as done for example by MAGENTA). The choice of such a parameter is not straight-
forward and our method usually performs better, regardless of the chosen parameter.
Third, we show that the null distribution of enrichment p-values for pathways that contain
genes in linkage disequilibrium is non-uniform due to an “over-counting” of gene association
signals. This is a potential source of type I error underestimation and our method corrects for
this phenomenon using a gene fusion approach, which considers genes in LD as single entities.
We have extensively evaluated the performance of Pascal for several real data sets. These
comparisons demonstrated the rigorous control of type I error and superior predictive power
in a wide range of trait and power settings in terms of enhanced precision-recall curves.
As an additional global measure of power, we considered the number of significantly
enriched pathways for a large number of GWAS meta-analysis summary statistics. On average,
our approach resulted in higher numbers of significant pathway scores than any binary enrich-
ment strategy. Given its precise type I error control, this provides additional evidence of
increased power for a wide range of traits. Indeed, the elevated rate of putatively involved path-
ways produced by our method not only reflects its higher sensitivity, but also already generates
new hypotheses for further studies.
Taken together, our results demonstrate the superior performance of our approach com-
pared to standard binary enrichment and rank-sum tests. Although methods with tuneable
parameters might yield improved results in a particular setting, it is difficult to predict the opti-
mal parameter choice. Indeed, the optimal parameter depends on sample size, as well as com-
plexity and heritability of the phenotype. Another issue with binary enrichment tests is that the
hypergeometric distribution is discrete, which leads to conservative p-values, especially if the
expected number of successful draws is low. Our pathway scoring approach avoids this prob-
lem. Also, our approach lends itself to naturally extending pathway scoring in case genes have
probabilistic membership in predefined pathways.
Users of our method will still have to make two choices: how to convert SNP p-values to
gene scores (max or sum gene scores), and how to transform gene scores into pathway scores
(empirical or chi-squared). We do not see evidence that one gene scoring method systemati-
cally outperforms the other in the context of our chi-squared pathway scoring method, while
there seems to be a better performance for sum gene score when using the empirical approach
(S8 Fig). To investigate this phenomenon we winsorized p-values (i.e. extreme p-values below
10−12 were set to 10−12) and saw that the max gene score combined with empirical sampling
suffered far less performance loss (S9 Fig). We therefore conclude that the power loss is due to
outlier gene scores. The max gene-scores can lead to very high gene scores for high-powered
studies. In the extreme case one gene might reach scores so high that it precludes detection of
pathways not containing that gene when the empirical sampling strategy is used.
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Future work could attempt to enhance several other aspects of our pathway enrichment
analysis. For example, here we mapped SNPs to genes only based on physical distance, while
potential improvements could be attained by incorporating additional information, such as
eQTL data[40] and functional annotations, to assign weights to different association signals
within a locus. While our approach is amenable to such a weighting scheme, this would poten-
tially require the introduction of tuneable parameters, which we avoided so far. Furthermore,
one may attempt to redefine gene sets based on external unbiased large-scale molecular data,
such as expression data, while so far we only used the established (but likely biased) pathway
collections[4]. To this end, we already integrated Pascal into a pipeline to analyze the connec-
tivity between trait-associated genes across over 400 tissue-specific regulatory, co-expression
and protein-protein interaction networks, further demonstrating its value for network-based
analysis of GWAS results (Marbach et al., submitted).
As an additional caveat, we should mention that Pascal uses the European 1KG sample as
reference population per default. This choice may not be appropriate if the studied sample is
not of European origin. In this case the user is encouraged to supply Pascal with the appropri-
ate reference panel. Also, SNPs with low MAF are by default excluded from the analysis,
because the low number of individuals in the European 1KG sample limits the accuracy of the
LD estimate for low frequency variants. If the user wishes to include lower frequency variants,
the use of a reference sample containing more individuals is recommended.
To conclude, Pascal implements fast and rigorous analytical methods into a single analysis
pipeline tailored for gene scoring and pathway enrichment analysis that can be run on a desk-
top computer. We thus hope that Pascal will be useful to the GWAS community in a range of
applications and play a pivotal role in leveraging the rich information encoded in GWAS
results both for single traits and—given its efficiency and power—in particular also for high-
dimensional molecular traits.
Our tool is available as a single standalone executable java package containing all required




The Pascal gene scoring method consists of the following steps (Fig 1A). First, we assign SNPs
to genes if they are located within a given window around the gene body. For the experiments
reported in this paper, we used windows extending 50kb up and downstream from the gene. A
reference population is required to estimate the correlation structure between Z-scores of SNP
association values. Here, we used the European population of the 1000 Genomes Project (1KG)
[22], which allows us to apply our approach flexibly to summary statistics from diverse panels
(HapMap, 1KG imputed, metaboChip or ImmunoChip).
Under the null hypothesis, it can be shown that the Z-scores of n SNPs in our gene region as
multivariate normal:
z  N nð0;ΣÞ
where S is the pair-wise SNP-by-SNP correlation matrix (see Section ‘Derivation of the sum
score’ for details).
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and
Tmax ¼ maxðz2i Þ;








where λi is the i-th eigenvalue of S. Its distribution function can be evaluated numerically (see
Section Algorithmic details for gene-score calculations for details). To estimate the null distri-
bution of Tmax we make use of the fact that
P½Tmax  t ¼ P½maxðjzijÞ  t ¼ 1 Pðjzij < t; i ¼ 1; 2; . . . nÞ:
This amounts to a rectangular integration over a multivariate normal, for which an efficient
algorithm is available[41]. The current implementation of this integration is suitable to esti-
mate p-values larger than 10−15. To approximate gene-wise p-values below this limit we multi-
ply the minimum p-value of SNPs in the region with the effective number of tests within the
gene (see Section Algorithmic details for gene-score calculation).
Gene fusion
Pathway analysis methods typically assume that the gene scores used to define pathway enrich-
ment are independent. However, functionally related genes often cluster on the genome and
harbor SNPs in LD, leading to correlated gene scores that violate this assumption. To circum-
vent this problem, we check for a given pathway if any of its genes that cluster physically close
on the chromosome are in LD. If so, for the calculation of the pathway score, we consider a sin-
gle entity (a so-called fusion-gene) consisting of all the SNPs of the gene cluster. We then
replace the genes in the cluster by this fusion-gene and calculate its gene score, but only for the
calculation of the score for this particular pathway. The pathway score is then computed from
the p-values of independent pathway genes and fusion genes that integrate the associational
signals from dependent pathway genes (Fig 1B). In this way, the LD structure of neighbouring
pathway genes is taken into account. Our gene scoring method facilitates this approach because
it is sufficiently fast and scalable for recomputing the scores of all fusion genes.
Pathway scores
For pathway analysis, we propose a parameter free enrichment strategy that does not require
the specification of a gene score threshold, and thus allows weakly associated genes to contrib-
ute to pathway enrichment. The general approach consists of three steps: (1) gene scores are
transformed so that they follow a target distribution, (2) a test statistic is computed by sum-
ming the transformed scores of pathway member genes and fusion-genes, and (3) analytic or
empirical methods are used to evaluate whether the observed test statistic is higher than
expected, i.e., the pathway is enriched for trait-associated genes. We considered two variants of
this approach for pathway scoring (see overview in S1 Fig). The first variant is termed as the
chi-squared method:
1. Gene score p-values are ranked such that the lowest p-value gets the highest rank. The rank
value is then divided by the number of genes plus one to obtain a uniform distribution.
2. Uniform distribution values are transformed by the w21-quantile function to obtain a w
2
1-dis-
tribution of gene scores.
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3. w21–gene scores of a given pathway of sizem are summed and tested against a
w2m-distribution.
The second variant is the empirical samplingmethod:




2. A raw pathway score for a pathway of sizem is computed by summing the transformed
gene scores for all pathway genes.
3. A Monte Carlo estimate of the p-value is obtained by sampling random gene sets of sizem
and calculating the fraction of sets reaching a higher score than gene set of the given
pathway.
We also tested a generalization of the chi-squared method where the inverse w21-quantile
transformation of the p-value ranks was replaced by the inverse Gamma-quantile transforma-
tion with varying shape parameter. For shape parameter of 0.5, the results coincide with results
from the chi-squared method.
For our benchmarking procedures we created a pathway library by combining the results
from KEGG[7,42], REACTOME[9] and BIOCARTA[10] that we downloaded fromMsigDB
[43].
Derivation of the sum-score
Let z be the vector of Z-statistics coming from regressing the phenotype on each of the n SNPs
within a gene-region. By construction, each Z-statistic has zero mean under the null. When
both the outcome trait and the genotypes are standardized, the linear regression Z-statistics are
essentially the scalar products of the genotype and the phenotype vectors. In other words, each
Z-statistic in the region represents a weighted average of the same set of independent, identi-
cally distributed random variables. It can be shown that the correlation between two such mix-
tures, i.e. two Z-statistics, equals to the correlation between the weights, i.e. the correlation
between the corresponding SNPs. Thus, the covariance matrix of z is simply the pairwise SNP-
by-SNP correlation matrix, denoted by S. Furthermore, the central limit theorem ensures that
in case of sufficiently large sample size the Z-statistics are normally distributed. These facts put
together yield that–under the null-hypothesis that no signal is present–z follows a multivariate
normal distribution, z  N nð0;ΣÞ. For a detailed derivation see supplementary material in Xu
et al[44] for example. Note that the between SNP correlation matrix S can be estimated from
external data[17,45].
The eigenvalue decomposition of S is
S ¼ ΓΛΓT ;
where Γ and Λ are the matrices of eigenvectors and eigenvalues, respectively. We see that mul-
tiplying z with the inverse of the square-root of S leads to a vector of independent random var-
iables. Let y be deﬁned as
y ¼ L1=2GTz;
then
y  N nð0; InÞ:
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It follows that






where λi is the i-th eigenvalue of S and w21 represents the chi-squared distribution.
Parameter settings
If not stated otherwise, our tool was always used with the following settings. We extended gene
regions by 50kb upstream and downstream for gene scoring. Only SNPs that reached a MAF of
0.05 in European 1KG sample were used. For pathway score calculation, we removed the HLA-
region. The gene-fusion parameter was set to 1Mb, so that when calculating a particular path-
way score, all pathway-member genes less than 1Mb apart were fused for the calculation. We
also removed genes containing more than 3000 SNPs except during speed benchmarking (Fig
2) where all SNPs were used.
Simulation settings for type I error control of the pathway scores
We used genotypes for 379 individuals from the EUR-1KG cohort[22]. Corresponding pheno-
type values were simulated as independent, standard normally distributed variables. Univariate
Z-scores for each of the 2,692,429 tested SNPs were calculated using linear regression. Simula-
tions were repeated 100 times. Since we investigated the impact of gene-fusion, the LD matrix
was estimated from the same data set to avoid any influence that might come from out-of-sam-
ple LD estimation.
Algorithmic details for gene-score calculations
Max-score. The algorithm first tries to use Monte Carlo simulation to derive p-values.
Should the p-value be too small to be estimated within a few Monte Carlo draws, the procedure
makes use of an algorithm for rectangular multivariate normal integration[41]. The implemen-
tation of the integration algorithm that is used is suitable to estimate p-values larger than 10−15.
In addition, this implementation is limited to correlation matrices of size below 1000 due to
numerical stability concerns. Therefore, SNPs that are in very high LD (r2> 0.98) are pruned
to lower the size of the correlation matrix. If more than 1000 SNPs fall into the gene or the
gene-wise p-value is below 10−15, we approximate the gene score by multiplying the minimal
SNP-wise p-value in the gene region by the effective number of tests. The effective number of
tests is calculated as the minimum number of principal components needed to explain 99.5%
of total variance[46].
Sum-score. The algorithm relies on the Davies algorithm to calculate distribution function
values of weighted sums of independent w21-distributed random variables[47]. In case of con-
vergence problems the Farebrother algorithm is used as a backup[48,49].
Web resources. A stand-alone executable for Pascal can be found at http://www2.unil.ch/
cbg/index.php?title=Pascal. The Pascal source code can be found at https://github.com/
dlampart/Pascal.
Supporting Information
S1 Fig. Overview of pathway scoring strategies in Pascal. Pathway scores are computed from
gene scores. The upper panel shows a typical gene score distribution, where the pathway gene
scores are indicated in black. In order to compute pathway scores, the original gene score p-val-
ues need to be transformed. To this end we use one of two strategies: in our empirical strategy
(lower left panel), gene score p-values are directly transformed with the inverse w21-quantile
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function F1w2
1
ð1 pÞ to obtain scores, which are then summed across all pathway genes. A
Monte Carlo estimate of the p-value is then obtained by sampling random gene sets of the
same size and calculating the fraction of sets reaching a higher score than that of the given
pathway. In the chi-squared method (bottom right panel), the gene score p-values are ﬁrst
ranked such that the lowest p-value ranks highest. The rank values are then divided by the
number of genes plus one to deﬁne new p-values (prank) that are distributed uniformly by deﬁ-
nition. From there, we proceed as for the empirical strategy just replacing p by prank. Also,
since the scores are guaranteed to be chi-squared distributed, the computation of their corre-
sponding p-value can be done analytically without any loss in precision.
(PDF)
S2 Fig. Comparison of results for different reference panels. Comparing p-values computed
using LD matrices from the European 1000 Genome reference panel and the CoLaus cohort.
GWAS summary statistics were taken from a large-scale blood-HDL level meta-analysis.
Results are compared for (a) max gene scores; (b) max gene scores excluding gene scores that
were computed with the effective number of tests approximation; and (c) sum gene scores.
There is good concordance in all cases.
(PDF)
S3 Fig. Comparison of max and sum gene scores.We compared max and sum gene scores
directly for a large-scale blood HDL level meta-analysis. Only gene scores up to 10−15 are dis-
played, which truncated 6 genes with very large max scores. R2 between the–log10-transformed
variables is 90%. Max scores tend to be larger when the two methods do not agree.
(PDF)
S4 Fig. Pathway scores for random phenotypes using max gene scores. P-values for 1077
pathways from our pathway library were computed for 100 random phenotypes using the Pas-
cal pipeline using max gene scores and chi-squared pathway integration strategy (a) without
merging of neighbouring genes and (b) with merging of neighbouring genes (gene-fusion strat-
egy). P-value distributions are represented by QQ-plots (upper panels) and histograms (lower
panels). Results are colour-coded according to the fraction of genes in a given pathway that
have a neighbouring gene in the same pathway, i.e. that are located nearby on the genome (dis-
tance<300kb). (a) P-values of pathways that contain genes in LD are strongly inflated without
correction. (b) The gene fusion approach provides well-calibrated p-values independently of
the number of pathway genes in LD.
(PDF)
S5 Fig. Performance of pathway enrichment methods for blood lipid traits and Crohn’s dis-
ease using sum of squares (SOCS) statistics for defining gene scores. Displayed is the mean
area under the precision-recall curve (AUC) for pathways identified using Pascal, a standard
hypergeometric test at various gene score thresholds, and a rank-sum test (vertical bars show
the standard error). We show results for the SOCS gene scores (MOCS gene score results are
similar, see Fig 4 in the main text). a) Results for four blood lipid traits. A reference standard
pathway list was defined as all pathways that show a significance level below 5×10−6, for any of
the tested threshold parameters for hypergeometric tests in the largest study of lipid traits to
date. The significance level of 5×10−6 corresponds to the Bonferroni corrected, genome-wide
significance threshold at the 0.5% level for a single method. For each phenotype, error bars
denote the standard error computed from three independent subsamples of the CoLaus study
(including 1500 individuals each). We see good overall performance of Pascal pathway scores,
whereas results for discrete gene sets vary widely with the particular choice for the threshold
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parameter of hypergeometric test. b) Results for Crohn’s disease using the same approach as in
(a). A reference standard pathway list was defined as all pathways that show a significance level
below 5×10−6 for any of the tested threshold parameters for hypergeometric tests in the largest
study of Crohn’s disease traits to date. We observe that the chi-squared strategy outperforms
all other strategies in this setting, whereas performance of the hypergeometric testing strategy
varies.
(PDF)
S6 Fig. Power of pathway scoring methods across diverse traits and diseases using sum of
squares (SOCS) statistics for defining gene scores. Bar heights represent the number of path-
ways found to be significant after Bonferroni correction. Within a given trait group, results are
aggregated for all tested GWAS studies. 65 GWAS had at least one significant pathway in one
of the tested method. For each GWAS, the raw number of significant pathways was divided by
the number of pathways found by the best performing method. This was done to avoid that a
few studies with many emerging pathways dominate. We show results for the SOCS gene
scores (MOCS gene score results are similar, see Fig 5). (a) Results are aggregated over all trait
groups. (b) Results for different trait groups.
(PDF)
S7 Fig. Power of pathway scoring methods stratified with respect to sample size. Only
GWAS studies for quantitative traits were used. Top panels (a,b) show results for max gene
scores and bottom panels (c,d) show results for sum gene scores. (a,c) Results for all studies
where the number of individuals was below 50,000. (b,d) Results for studies with sample sizes
above 50,000. We see power gains in all cases. The improvements are particularly pronounced
in lower powered GWAS.
(PDF)
S8 Fig. Power comparison max and sum gene scores for pathway analysis. Bar heights repre-
sent the number of pathways found to be significant after Bonferroni correction. Within a
given trait group, results are aggregated for all tested GWAS studies. For each GWAS, the raw
number of significant pathways was divided by the number of pathways found by the best per-
forming method. Results for SOCS and MOCS as well as the chi-square and empirical pathway
scores are displayed. We observe a drop in performance for the combination of MOCS gene
scores with empirical pathway scores.
(PDF)
S9 Fig. Power analysis for max gene scores with capped gene scores. Bar heights represent
the number of pathways found to be significant after Bonferroni correction. Within a given
trait group, results are aggregated for all tested GWAS studies. For each GWAS, the raw num-
ber of significant pathways was divided by the number of pathways found by the best perform-
ing method. Max gene scores using empirical sampling pathway scores (emp) and chi-squared
pathway scores (chi2) are compared to max gene scores combined with empirical sampling,
where outlier gene scores (p-value<10−12) are set to 10−12 (empCapped). We chose the cap-
ping value such that the maximum–log10 p-value was roughly in the middle between genome
wide significance threshold (8) and the maximum value that can be calculated for the sum sta-
tistic (15).
(PDF)
S10 Fig. Power of Pascal pathway scoring methods compared to aggregated hypergeomet-
ric scores (MOCS). The same data as in Fig 5 is plotted here. However, instead of comparing
Pascal pathway scoring methods with results for all hypergeometric threshold separately, we
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defined a new aggregated pathway score that picks the optimal threshold for each pathway
over a range of hypergeometric threshold and correcting for the multiple number of tests by
Bonferroni correction. Results for different sets of thresholds are displayed. Set1 refers to the
complete set of thresholds (i.e.: 25%, 15%, 10%, 5%, 2%, 1%, 0.25%, 0.1%). Set2 refers to a set
with thresholds more ‘spread out’ (i.e.: 25%, 5%, 1%, 0.25). We see that Pascal has better perfor-
mance, except when combining the ‘empirical sampling’ pathway scoring method with max
gene scores.
(PDF)
S11 Fig. Power of Pascal pathway scoring methods compared to aggregated hypergeomet-
ric scores (SOCS). The same data as in Fig 5 is plotted here. However, instead of comparing
Pascal pathway scoring methods with results for all hypergeometric threshold separately, we
defined a new aggregated pathway score that picks the optimal threshold for each pathway
over a range of hypergeometric threshold and correcting for the multiple number of tests by
Bonferroni correction. Results for different sets of thresholds are displayed. Set1 refers to the
complete set of thresholds (i.e.: 25%, 15%, 10%, 5%, 2%, 1%, 0.25%, 0.1%). Set2 refers to a set
with thresholds more ‘spread out’ (i.e.: 25%, 5%, 1%, 0.25). We see that Pascal has better perfor-
mance.
(PDF)
S12 Fig. Power of gamma distribution for pathway analysis (MOCS). Bar heights represent
the number of pathways found to be significant after Bonferroni correction. Different bars sig-
nify results for a different gamma shape parameter value. For each GWAS, the raw number of
significant pathways was divided by the number of pathways found by the best performing
method. Upper left panel ‘All’ refers to all traits stacked. We present here MOCS gene score
based results. 52 GWAS showed at least one significant pathway in one of the evaluated scenar-
ios.
(PDF)
S13 Fig. Power of gamma distribution for pathway analysis (SOCS). Bar heights represent
the number of pathways found to be significant after Bonferroni correction. Different bars sig-
nify results for a different gamma shape parameter value. For each GWAS, the raw number of
significant pathways was divided by the number of pathways found by the best performing
method. Upper left panel ‘All’ refers to all traits stacked. We present here MOCS gene score
based results. 60 GWAS showed at least one significant pathway in one of the evaluated scenar-
ios.
(PDF)
S14 Fig. Distribution of pathway scores for simulated phenotypes influenced by causal
SNPs in coding regions.We first sampled 50 random SNPs assayed in CoLaus in or close to
coding regions. Using the genotypes of the CoLaus study we then simulated phenotypes by
adding up the sampled 50 SNPs with a normally distributed effect size with a variance of 0.04
plus Gaussian noise (with a variance of 1). We then ran GWAS for the simulated phenotype to
obtain association summary statistics. The experiment was repeated 50 times. On average, this
resulted in 18 independent, genome-wide significant gene score hits for each simulated GWAS
(for the MOCS statistic). We applied Pascal to compute pathway scores for each of the 50 sim-
ulated GWAS. We found that the resulting pathway scores are well calibrated, i.e., they do not
show inflation or deflation regardless of the setting used (max or sum gene score, chi2 or
empirical enrichment test). The QQ-plots show the median value for each quantile across the
50 simulated GWAS. The shaded areas correspond to 95% confidence intervals for the median
(estimated from 2000 bootstrap samples of size 50, with replacements). Similar results were
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obtained when varying the type and number of simulated causal SNPs and their effect size.
(PDF)
S15 Fig. Distribution of pathway scores for simulated phenotype influenced by causal
SNPs in coding and non-coding regions. These QQ-plots correspond to an analysis equiva-
lent to that of S14 Fig but with 50 SNPs chosen uniformly from all SNPs assayed in CoLaus,
rather than from genic regions only. On average, this resulted in 12 independent, genome-wide
significant gene score hits for each simulated GWAS (using the MOCS statistic). Note that this
does not completely exclude the possibility of less well-calibrated scores in other settings. Devi-
ations from perfectly calibrated scores may occur in the cases where true SNP associations are
present, because the gene wise test statistic may have varying power for different genes depend-
ing on the genetic architecture of the associated phenotype and on certain gene properties
(such as gene length, LD structure, SNP coverage, or SNP allele frequency). If a set of pathways
contains many pathways enriched (or depleted) for genes with such confounding factors, infla-
tion or deflation is possible.
(PDF)
S1 Table. Details of GWAS used. Details of the 118 GWAS that we used for comparing Pascal
with other methods.
(TXT)
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